Citations
Abel E, Lebwohl M (2008). Psoriasis. In EG Nabel, ed., ACP Medicine, section 2, chap. 3. Hamilton, ON: BC Decker.
Gudjonsson JE, et al. (2002). HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. Journal of Investigative Dermatology, 118(2): 362-365.
Gudjonsson JE, Elder JT (2008). Psoriasis. In K Wolff et al., eds., Fitzpatrick's Dermatology in General Medicine, 7th ed., vol. 1, pp. 169-193. New York: McGraw-Hill Medical.
Behnam SM, et al. (2005). Smoking and psoriasis. Skinmed, 4(3): 174-176.
Setty AR, et al. (2007). Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Archives of Internal Medicine, 167(15): 1670-1675.
Naldi L, Rzany B (2009). Psoriasis (chronic plaque), search date August 2007. Online version of BMJ Clinical Evidence: http://www.clinicalevidence.com.
Menter A, Griffiths CEM (2007). Current and future management of psoriasis. Lancet, 370(9583): 272-284.
Fortune DG, et al. (2002). A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. British Journal of Dermatology, 146(3): 458-465.
Abramowicz M (2008). Drugs for acne, rosacea and psoriasis. Treatment Guidelines From The Medical Letter, 6(75): 75-82.
Reich K, et al. (2005). Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet, 366(9494): 1367-1374.
Krueger GG, et al. (2005). Patient-reported outcomes of psoriasis improvement with etanercept therapy: Results of a randomized phase III trial. British Journal of Dermatology, 153(6): 1192-1199.
Aloe (2004). In A DerMarderosian, J Beutler, eds., Review of Natural Products. St. Louis: Wolters Kluwer Health.
Other Works Consulted
Giezen TJ, et al. (2008). Safety-related regulatory actions for biologicals approved in the United States and the European Union. Journal of the American Medical Association, 300(16): 1887-1896.
Kimball AB, et al. (2008). National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal of the American Academy of Dermatology, 58(6): 1031-1042.
Nestle FO, et al. (2009). Psoriasis. New England Journal of Medicine, 361(5): 496-509.
Schmitt J, et al. (2008). Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials. British Journal of Dermatology, 159(3): 513-526.
| By: | Healthwise Staff | Last Revised: January 13, 2010 |
| Medical Review: | Kathleen Romito, MD - Family Medicine Alexander H. Murray, MD, FRCPC - Dermatology | |
1995-2011 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.